We showed that cholesterol-conjugated anti-Il6 siRNA, selected based on the results of preliminary in vitro screening, has a dose-dependent therapeutic effect in LPS-induced ALI, reducing the number of cells in BAL fluid and the level of Il6 mRNA in them, as well as reducing the severity of inflammatory and edema changes in the lungs. Here, IL6 is linked to acute respiratory distress syndrome.